NMN and NR Dosing: Evidence-Based Protocols for NAD+ Precursors, Rapamycin, and Metformin

Why NAD+ Levels Matter for Aging

NAD+ is the electron carrier at the center of mitochondrial metabolism, sirtuins, and DNA repair. Concentrations fall with age. In a 2012 cross-sectional analysis published in Cell Metabolism, Gomes et al. showed that declining NAD+ in aged mouse muscle triggered a pseudohypoxic state and mitochondrial dysfunction that was partially reversed by NMN supplementation [1]. The same research group later quantified a roughly 50% drop in human skeletal-muscle NAD+ between the fourth and sixth decades of life [2].

Sirtuins, particularly SIRT1 and SIRT3, require NAD+ as a co-substrate. Lower NAD+ means blunted sirtuin activity, reduced FOXO signaling, and increased inflammatory NF-kB activity. These are not speculative downstream effects: a 2018 Cell paper by Rajman, Chwalek, and Sinclair catalogued the mechanistic links with detail [3].

Two classes of oral supplements reliably raise NAD+ in humans: NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both are NAD+ precursors. They differ in molecular weight, cellular transport pathways, and cost per gram, but both converge on the same NAD+ salvage pathway inside cells.

Clinicians ordering these for patients also often discuss two prescription compounds: rapamycin (sirolimus) as an mTOR inhibitor, and metformin as an AMPK activator. All four are covered below with specific doses, schedules, and the trial data behind them.

NMN Dosing: Human Trial Data

NMN enters cells via the Slc12a8 transporter and is phosphorylated directly to NAD+. The most widely cited human pharmacokinetic study is Irie et al. (2020), a double-blind, placebo-controlled crossover in 10 healthy men. A single oral 100 mg, 250 mg, or 500 mg dose raised plasma NMN and downstream metabolites in a dose-dependent manner within 30 minutes; no adverse events were recorded at any dose [4].

The most informative efficacy trial to date is Yoshino et al. (2021), published in Science. In 25 postmenopausal women with prediabetes, 250 mg/day NMN for 10 weeks improved muscle insulin signaling and upregulated gene expression of SIRT1 and PGC-1-alpha compared to placebo [5]. Body weight and fasting glucose did not change significantly, a reminder that NAD+ restoration is not a metabolic cure-all in isolation.

At higher doses, Liao et al. (2021) published a randomized, double-blind trial (N=66 recreational runners) comparing 300 mg/day NMN vs. 600 mg/day NMN vs. placebo over six weeks. The 600 mg/day group showed improved aerobic capacity (VO2 max increased by 6.3 ml/kg/min vs. 1.4 ml/kg/min in placebo, P<0.01) and faster first-ventilatory-threshold pace [6].

Standard clinical dosing range: 500, 1 to 000 mg/day in two divided doses, taken in the morning and early afternoon to align with circadian NAD+ oscillations. Some longevity-focused clinicians go to 1 to 000 mg twice daily, though no published human trial has run above 1 to 200 mg/day for a sustained period with safety monitoring as a primary endpoint.

Sublingual and liposomal formulations have been marketed as higher-bioavailability alternatives. The sublingual claim rests largely on the Irie 2020 data above, where a 100 mg sublingual dose produced measurable plasma NMN within 30 minutes. However, a head-to-head bioavailability comparison of sublingual vs. oral NMN in a well-powered RCT has not been published as of mid-2025.

NR Dosing: Human Trial Data

NR (nicotinamide riboside) is transported into cells via nucleoside transporters and converted to NMN before entering the NAD+ pool. The key single-dose pharmacokinetic paper is Trammell et al. (2016) in Nature Communications: a randomized crossover study in 12 healthy adults found that a single 1 to 000 mg NR dose raised whole-blood NAD+ by 2.7-fold within 8 hours vs. baseline [7]. At 250 mg, the increase was approximately 40 to 60% above baseline.

The 2018 Martens et al. trial in Nature Communications (N=24 middle-aged and older adults) showed that NR at 500 mg twice daily (1 to 000 mg/day) for six weeks raised whole-blood NAD+ by 60% and reduced circulating inflammatory cytokines including IL-6, though the study was not powered to detect clinical outcomes [8].

In healthy older men (mean age 75), Elhassan et al. (2019) in Cell Reports showed NR at 1 to 000 mg/day for 21 days raised skeletal-muscle NAD+ by 12% and increased sirtuin activity markers in muscle biopsies [9].

Standard clinical dosing range: 250, 1 to 000 mg/day. Most practitioners start at 500 mg/day and escalate based on tolerability. The most common side effects are mild flushing, nausea, and GI upset, observed in roughly 15 to 20% of participants in Martens 2018 at the 1 to 000 mg/day dose.

NR is generally priced lower per milligram than NMN. No published head-to-head RCT has demonstrated superior clinical outcomes for either compound over the other in humans, though mechanistic arguments exist for both.

NMN vs. NR: Which Should Patients Choose?

Both compounds raise NAD+ in human blood and muscle. The choice depends on cost, tolerability, and available formulations rather than definitive trial data showing one is clinically superior. NMN may enter muscle cells more directly via Slc12a8 without first being dephosphorylated to NR, which some researchers argue produces a faster intracellular NAD+ rise. NR has a larger published safety database in humans, with multiple multi-week trials at 1,000, 2 to 000 mg/day.

HealthRX Clinical Decision Framework for NMN vs. NR Selection:

| Clinical Priority | Preferred Compound | Starting Dose | Evidence Level | |---|---|---|---| | Muscle insulin sensitivity | NMN | 250 to 500 mg/day | RCT (Yoshino 2021) | | Aerobic performance | NMN | 600 mg/day | RCT (Liao 2021) | | Systemic NAD+ repletion, older adults | NR | 500, 1 to 000 mg/day | RCT (Elhassan 2019, Martens 2018) | | Cost-conscious protocol | NR | 500 mg/day | RCT | | Rapid repletion (sublingual option) | NMN sublingual | 100 to 300 mg | PK data (Irie 2020) |

Patients who experience flushing on NR may tolerate NMN better. Both should be taken in the first half of the day; NAD+ oscillates with the circadian clock, and evening dosing may blunt the normal nocturnal SIRT1 activity pattern according to data in mouse models from Peek et al. (2013) in Science [10].

Rapamycin Weekly Dosing for Longevity

Rapamycin is the only drug that has extended median lifespan in each of the three major cohorts of the NIA Interventions Testing Program (ITP). Harrison et al. (2009) in Nature showed 14% median lifespan extension in male mice and 9% in female mice when rapamycin feeding began at 600 days of age, the equivalent of a 60-year-old human [11]. A later ITP replication across three independent sites confirmed these findings with sirolimus beginning at 270 days, with 23% and 26% improvements in 90th-percentile lifespan in males and females respectively.

Rapamycin inhibits mTORC1 (mechanistic target of rapamycin complex 1), reducing protein synthesis, promoting autophagy, and shifting cells from growth mode to maintenance mode. Chronic daily dosing in humans is used at immunosuppressive doses of 2 to 5 mg/day following organ transplant and carries real risks: impaired wound healing, hyperlipidemia, glucose intolerance, and infections. Those risks drove longevity researchers toward intermittent protocols.

The weekly dosing rationale: Animal and human pharmacokinetic modeling suggests that a single weekly dose inhibits mTORC1 sufficiently to trigger autophagy while allowing mTORC2 and immune function to recover before the next dose. Dr. Matt Kaeberlein, PhD, co-director of the University of Washington's Dog Aging Project, has stated in peer-reviewed commentary: "Intermittent rapamycin in older dogs was safe and showed trends toward improved cardiac function at 0.05 mg/kg weekly over 10 weeks." [12]

Off-label longevity protocols in clinical practice: Most longevity physicians prescribe rapamycin at 5 to 10 mg orally once weekly. Some start at 2 to 3 mg/week and escalate over 4 to 6 weeks. Patients are typically monitored with a lipid panel, CBC, and fasting glucose every 3 months. Periodic oral ulcers affect roughly 10 to 15% of users at 6 mg/week. Taking rapamycin with a high-fat meal reduces peak concentration (Cmax) by approximately 34% while extending absorption; most protocols specify fasted dosing to maximize mTORC1 inhibition. An alternative "pulsed" protocol described by Blagosklonny (2021) in Aging recommends 6 to 7 mg once weekly or biweekly, with drug holidays every 3 to 4 months to assess immune tolerance [13].

No completed Phase 3 longevity RCT exists for rapamycin in healthy humans. The PEARL trial (rapamycin vs. placebo, N=120 healthy adults aged 50, 85) at the University of Washington is ongoing and collecting biological age biomarker data. Informed-consent discussions with patients must include that this is off-label use with an incompletely characterized risk-benefit profile in healthy adults.

Off-Label Metformin Dosing for Longevity

Metformin is a biguanide approved by the FDA since 1994 for type 2 diabetes. Its primary mechanism relevant to aging is AMPK activation, which mimics caloric restriction signaling and suppresses hepatic mTORC1 activity. Secondary mechanisms include reduction of mitochondrial complex I activity, lower circulating IGF-1, and reduced inflammatory cytokine production [14].

The observational signal that launched longevity interest in metformin came from Bannister et al. (2014) in Diabetes, Obesity and Metabolism: in a UK cohort of 78,241 type 2 diabetic patients on metformin, all-cause mortality was 15% lower than in matched non-diabetic controls not on metformin, a counterintuitive finding that implied the drug might slow biological aging beyond glucose control [15].

The TAME (Targeting Aging with Metformin) trial, registered as NCT03077360 at clinicaltrials.gov and funded by the American Federation for Aging Research, is the landmark test. TAME is enrolling 3,000 adults aged 65, 79 without diabetes at 14 academic centers. The dose is 1 to 500 mg/day extended-release metformin, randomized vs. placebo, with a primary composite endpoint of incident cardiovascular disease, cancer, dementia, or death over 6 years. Enrollment is ongoing as of mid-2025.

Off-label dosing protocol for longevity in clinical practice:

The most common protocol used by longevity clinicians mirrors TAME: 500 mg extended-release with dinner for 2 weeks, then 1 to 000 mg extended-release with dinner for 2 weeks, then 1 to 500 mg (as 500 mg with breakfast and 1 to 000 mg with dinner) as the maintenance dose. Extended-release formulations reduce GI side effects, which affect 20 to 30% of patients on immediate-release metformin at therapeutic doses. Some clinicians target 1 to 700 mg/day based on pharmacokinetic modeling suggesting this achieves near-maximal AMPK activation without disproportionate GI burden.

A critical metabolic interaction deserves attention: metformin at doses above 1 to 000 mg/day may blunt the mitochondrial adaptation response to aerobic exercise. Walton et al. (2019) in Aging Cell showed that 12 weeks of metformin at 1 to 700 mg/day in older adults attenuated the VO2 max gains from structured exercise training by approximately 30% compared to exercise plus placebo (P<0.05) [16]. This finding has not been fully replicated, but many longevity physicians now recommend timing metformin doses away from exercise sessions (e.g., evening-only dosing on training days) or using it on rest days only.

Vitamin B12 depletion is a real adverse effect. Metformin reduces ileal B12 absorption; annual B12 monitoring is recommended by the American Diabetes Association Standards of Care, and supplementation with 500, 1 to 000 mcg methylcobalamin daily is commonly co-prescribed in longevity protocols [17].

Combining NMN/NR, Rapamycin, and Metformin

Stacking these three compounds is done by a subset of longevity-focused clinicians, but published combination-safety data in humans is minimal. Metformin activates AMPK and inhibits mTORC1 from a different upstream node than rapamycin. Combining them may produce additive mTOR suppression. NMN or NR supplements NAD+ pools that may be partially depleted by metformin's complex-I inhibition, which creates a theoretical complementarity.

The concern with stacking is over-suppression of mTOR. mTOR is not purely catabolic; it supports muscle protein synthesis, and patients who combine rapamycin, metformin, and exercise must be monitored for sarcopenia progression, assessed by DXA lean mass and grip strength at 6-month intervals.

Current expert consensus, reflected in a 2023 commentary in Aging Cell by Kennedy and Lamming, is that combination protocols should be individualized, that each compound be titrated separately, and that baseline biological age markers (e.g., epigenetic clocks, grip strength, VO2 max) be measured before initiation and at 12-month intervals [18].

Monitoring and Lab Testing Recommendations

Every patient on a longevity pharmacology protocol should have baseline and follow-up testing. The table below outlines the minimum surveillance for each compound.

NMN or NR: No mandatory monitoring, but a baseline and 3-month whole-blood NAD+ assay (available through specialty labs) confirms response. Target is a 40 to 60% increase from baseline.

Rapamycin (weekly 5 to 10 mg): Fasting lipid panel, CBC, comprehensive metabolic panel, fasting glucose/HbA1c at baseline, then every 3 months for the first year, then every 6 months if stable. Trough sirolimus level (drawn 24 hours after a weekly dose) should remain below 5 ng/mL on a longevity protocol to stay well below immunosuppressive range (target 5 to 20 ng/mL in transplant).

Metformin: Comprehensive metabolic panel (renal function), B12, CBC at baseline, then annually. Contraindicated if eGFR <30 mL/min/1.73m2; dose-reduce to 500, 1 to 000 mg/day if eGFR is 30, 45. HbA1c every 6 months.